Artialis and Phylogene partnership in musculoskeletal diseases

Artialis and Phylogene join forces on clinical research for studying innovative new treatments targeting musculoskeletal disorders





Artialis and Phylogene join forces on clinical research for studying innovative new treatments targeting musculoskeletal disorders

Artialis is a Belgian CRO, founded in 2010 and specialized in musculoskeletal diseases including osteoarthritis, arthritis, and sarcopenia. Artialis supports pharmaceutical, food and biotechnology industry clients from the early stages of their product development (R&D) to post-marketing phases, with non-clinical and clinical studies. In addition, Artialis is an expert in the field of biomarker development and biotesting assays to evaluate the efficacity of novel treatments. The company has already marketed several assay kits for monitoring the development of osteoarthritis in humans.

Phylogene is a French CRO specialized in *in vitro* studies based on "omics" techniques. The company conducts, among others, mass spectrometry, non-targeted proteomics and metaproteomics as well as bioinformatics studies which allow, through the quantification of proteins and their post-translational modifications, to highlight specific changes in signalling pathways related to treatment administration. In addition, genomic, metagenomic, and metabolomic approaches complete the package of available services.

The pooling of skills, expertise, and technologies of these two partners enable to explore new perspectives for the effects and mechanisms of action of novel therapies. This partnership represents an undeniable commercial advantage for Artialis and Phylogene and has already convinced a company focusing on healthcare for a project worth several million euros.

With Artialis, Phylogene has now access to biological fluid samples, faeces, and biopsies (cartilage, bones, and muscles), which could allow potential clients to evaluate the effects of a new treatment through proteomics, non-targeted metaproteomics and bioinformatics techniques.

Thanks to the collaboration with Phylogene, Artialis can now extend its range of non-targeted techniques by focusing on "omics" and bioinformatic analyses in order to identify the mechanism(s) of action of products tested in non-clinical and clinical studies and develop a panel of specific biomarkers related to new treatments.





More informations about Artialis:

Address: 11, Avenue de l'Hôpital (Sart-Tilman, GIGA +3), 4000 LIEGE - Belgique Artialis website : Artialis

More informations about Phylogene:

Address: 62, Route Nationale 113, 30620 BERNIS – France
Phylogene website: Phylogene